Procedural Predictors for Bioresorbable Vascular Scaffold Thrombosis: Analysis of the Individual Components of the “PSP” Technique
Open Access
- 15 January 2019
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 8 (1) , 93
Abstract
The technique used at the time of implantation has a central role in determining the risk of thrombosis in bioresorbable vascular scaffolds (BRS). Different definitions of the “optimal” implantation technique exist, however. The impact of individual procedural characteristics on the risk of scaffold thrombosis (ScT) was evaluated in a single-center observational study that enrolled 657 patients (79% males, mean age 63 ± 12 years) with 763 lesions who received a total of 925 BRS for de novo lesions. During a median 1076 (762–1206) days’ follow-up there were 28 cases of thrombosis. Independent predictors of ScT included the use of predilatation balloons bigger than the nominal BRS diameter (hazard ratio (HR) = 0.4 (0.16–0.98), p = 0.04), sizing (implantation in vessels with reference vessel diameter >3.5 mm or p = 0.0002) and the degree of vessel expansion (ratio of minimum lumen to reference vessel diameter, HR: 0.005 (0.0001–0.23), p = 0.007). In addition, a mild BRS oversizing (final BRS diameter to vessel diameter 1.14–1.28) was associated with a lower thrombosis risk, whereas undersizing and more severe oversizing (final BRS diameter to vessel diameter 1.35, respectively) were associated with an increased risk of ScT (HR = 0.13 (0.02–0.59), p = 0.0007). In conclusion, different components of the “optimal” technique have different impacts on the risk of BRS thrombosis. Besides predilatation with a balloon larger than the BRS diameter, correct vessel size selection and a mild to moderate oversizing appear to be protective.Keywords
This publication has 32 references indexed in Scilit:
- Predictors of bioresorbable scaffold failure in STEMI patients at 3 years follow-upInternational Journal of Cardiology, 2018
- Characteristics, Predictors, and Mechanisms of Thrombosis in Coronary Bioresorbable ScaffoldsJACC: Cardiovascular Interventions, 2017
- Incidence, Clinical Presentation, and Predictors of Clinical Restenosis in Coronary Bioresorbable ScaffoldsJACC: Cardiovascular Interventions, 2017
- Effect of Post-Dilatation Following Primary PCI With Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting Metallic Stent ImplantationJACC: Cardiovascular Interventions, 2017
- Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic StentsJACC, 2017
- 10-Year Clinical Outcome After Randomization to Treatment by Sirolimus- or Paclitaxel-Eluting Coronary StentsJACC, 2017
- Bioresorbable Coronary Scaffold ThrombosisJACC, 2016
- 1-year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysisThe Lancet, 2016
- Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trialsThe Lancet, 2016
- Role of Endothelial Shear Stress in Stent Restenosis and ThrombosisJACC, 2012